Variability in abciximab (ReoPro®) prescribing: Evidence based or budget driven?

Pharmacoepidemiology and Drug Safety

Volumn 11, Issue 2, 2002, Pages 135-141

  Zwart van Rijkom, J E F ^a,b   Leufkens, H G M ^a   Simoons, M L ^c   Broekmans, A W ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Abciximab; Budgets; Diffusion of innovation; Glycoprotein IIb IIIa receptor blockade; Prescribing patterns

Indexed keywords

ABCIXIMAB;

ARTICLE; BUDGET; CONTROLLED STUDY; COOPERATION; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; CORRELATION ANALYSIS; DRUG INDICATION; DRUG USE; EVIDENCE BASED MEDICINE; FINANCIAL MANAGEMENT; HEART INFARCTION; HUMAN; INTERVIEW; LINEAR REGRESSION ANALYSIS; MEDICAL SPECIALIST; NETHERLANDS; PATIENT SELECTION; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; EVIDENCE-BASED MEDICINE; HOSPITALS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; LINEAR MODELS; NETHERLANDS; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PRESCRIPTIONS, DRUG;

EID: 0036241892     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.689     Document Type: Article

References (35)

1. Outcomes research, cost containment, and the fear of health care rationing
2. Challenges to the economic evaluation of new biotechnological interventions in health care
3. Assessment of biotechnology drugs: What are the issues?
4. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
5. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina
6. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study
7. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
8. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
9. Abciximab: A new antiplatelet agent for use in coronary angioplasty Ned
10. Costs and effects in therapy for acute coronary syndromes: The case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study
11. Enthusiasm, reality, and cost-effectiveness analysis
12. Economic considerations in the use of the platelet GP IIb/IIIa inhibitor abciximab in percutaneous coronary intervention
13. Abciximab. An updated review of its use in ischaemic heart disease
14. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II)
15. Routine use of abciximab in coronary stenting?
16. Costs and effects of c7E3 in high risk PTCA patients. An indirect analysis for the Netherlands
17. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial
18. Marketing medicines through randomised controlled trials: The case of interferon
19. Abciximab therapy in percutaneous intervention: Economic issues in the United States
20. Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: What more needs to be proven?
21. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
22. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
23. Lipid-lowering therapy in low-risk patients
24. Prevention of coronary heart disease in clinical practice
25. Cost and outcomes analysis of abciximab use in a community teaching hospital
26. Abciximab therapy and unplanned coronary stent deployment: Favorable effects on stent use, clinical outcomes, and bleeding complications
27. Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients
28. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction
29. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II
30. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction Platelet
31. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
32. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
33. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina